Results 151 to 160 of about 117,202 (259)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

N-aldehyde-modified phosphatidylethanolamines generated by lipid peroxidation are robust substrates of N-acyl phosphatidylethanolamine phospholipase D. [PDF]

J Lipid Res
Fadaei R, Bernstein AC, Jenkins AN, Pickens AG, Zarrow JE, Alli-Oluwafuyi AM, Tallman KA, Davies SS.   +7 more
europepmc   +1 more source

Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance. [PDF]

ACS Med Chem Lett, 2022
May-Dracka TL, Gao F, Hopkins BT, Hronowski X, Chen T, Chodaparambil JV, Metrick CM, Cullivan M, Enyedy I, Kaliszczak M, Kankel MW, Marx I, Michell-Robinson MA, Murugan P, Kumar PR, Rooney M, Schuman E, Sen A, Wang T, Ye T, Peterson EA.   +20 more
europepmc   +1 more source

New Developments in Phospholipase D [PDF]

Journal of Biological Chemistry, 1997
openaire   +2 more sources

Atrial natriuretic peptide counteracts aldosterone secretion by preventing acute angiotensin II‐induced cAMP signalling

British Journal of Pharmacology, EarlyView.
Background and Purpose Aldosterone plays a key role in blood pressure and volume regulation. Enhanced aldosterone secretion contributes to cardiovascular and renal diseases. Therefore, inhibitors of aldosterone receptors and synthase are essential drugs for the treatment of hypertension and heart failure.
Sanika Mohagaonkar, Egor B. Skryabin, Bettina M. Buchholz, Michaela Kuhn, Celso E. Gomez‐Sanchez, Stepan Gambaryan, Viacheslav O. Nikolaev   +6 more
wiley   +1 more source

Predictive analysis of B-cell antigenic epitopes in phospholipase D toxins from <i>Loxosceles</i> spiders. [PDF]

Toxicon X
Catalán A, García C, Sambra V, Cadena N, Rojas J, Arán-Sekul T, San Francisco J, Vásquez-Saez V, Muñoz C, Vásquez A, Araya JE.   +10 more
europepmc   +1 more source

Dualsteric and dual‐acting modulation of muscarinic receptors by antagonist KH‐5

British Journal of Pharmacology, EarlyView.
Abstract Background and purpose Muscarinic acetylcholine receptors are key therapeutic targets, and ligands engaging both orthosteric and allosteric sites may offer improved selectivity and efficacy. Here, we investigated whether the muscarinic antagonist KH‐5 acts as a dualsteric antagonist and defined its mode of interaction with muscarinic receptors.
Alena Janoušková‐Randáková, Eva Dolejší, Nikolai Chetverikov, Jan Jakubík   +3 more
wiley   +1 more source

Development and Evaluation of Indole-Based Phospholipase D Inhibitors for Lung Cancer Immunotherapy. [PDF]

J Med Chem
Song D, Lim SH, Kim Y, Lee H, Kim T, Lim H, Min DS, Han G.   +7 more
europepmc   +1 more source

Study on the mechanism of efficient extracellular expression of toxic streptomyces phospholipase D in Brevibacillus choshinensis under Mg²⁺ stress. [PDF]

Microb Cell Fact, 2022
Chen S, Xiong W, Zhao X, Luo W, Yan X, Lu Y, Chen C, Ling X.   +7 more
europepmc   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, EarlyView.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source